Abstract
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to singleagent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.
Keywords: ARDS, ALI, inflammatory lung injury, lung injury therapy, anti-inflammatory therapy, surfactant therapy, INO therapy, antioxidants, pharmacotherapy
Current Medicinal Chemistry
Title: Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome
Volume: 15 Issue: 19
Author(s): Krishnan Raghavendran, Gloria S. Pryhuber, Patricia R. Chess, Bruce A. Davidson, Paul R. Knight and Robert H. Notter
Affiliation:
Keywords: ARDS, ALI, inflammatory lung injury, lung injury therapy, anti-inflammatory therapy, surfactant therapy, INO therapy, antioxidants, pharmacotherapy
Abstract: Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to singleagent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.
Export Options
About this article
Cite this article as:
Raghavendran Krishnan, Pryhuber S. Gloria, Chess R. Patricia, Davidson A. Bruce, Knight R. Paul and Notter H. Robert, Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome, Current Medicinal Chemistry 2008; 15 (19) . https://dx.doi.org/10.2174/092986708785132942
DOI https://dx.doi.org/10.2174/092986708785132942 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Synthesis, Cytotoxicity and Docking Simulation of Novel Annulated Dihydroisoquinoline Heterocycles
Mini-Reviews in Medicinal Chemistry Free Fatty Acids-Sensing G Protein-Coupled Receptors in Drug Targeting and Therapeutics
Current Medicinal Chemistry Identifying the Hub Proteins from Complicated Membrane Protein Network Systems
Medicinal Chemistry The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area
Current Topics in Medicinal Chemistry Combating the Progression of Novel Coronavirus SARS-CoV-2 Infectious Disease: Current State and Future Prospects in Molecular Diagnostics and Drug Discovery
Current Molecular Medicine Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19
Endocrine, Metabolic & Immune Disorders - Drug Targets <i>Caralluma edulis</i> (Apocynaceae): A Comprehensive Review on its Traditional Uses, Phytochemical Profile and Pharmacological Effects
Current Topics in Medicinal Chemistry Microwave and Conventional Method Assisted Synthesis of 2-(substituted) -3-(4-methoxybenzyl) Thiazolidin-4-ones Using ZrOCl2·8H2O as a Catalyst
Current Microwave Chemistry Prader-Willi Syndrome: Obesity due to Genomic Imprinting
Current Genomics HIV-1 Fitness and Disease Progression: Insights from the SIV-Macaque Model
Current HIV Research New Synthetic Antibiotics for the Treatment of Enterococcus and Campylobacter Infection
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of 2, 3-Diaryl substituted-1, 3-thiazolidin-4-ones as Anti-HIV Agents
Medicinal Chemistry Targeting HIV-1 gp41 in Close Proximity to the Membrane Using Antibody and Other Molecules
Current Topics in Medicinal Chemistry The Tetrahydroisoquinoline Scaffold in ABC Transporter Inhibitors that Act as Multidrug Resistance (MDR) Reversers
Current Topics in Medicinal Chemistry Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Synthesis, Molecular Docking and Evaluation of 3-{4-[2-amino-4-(substitutedphenyl)-2H-[1, 3] oxazin/thiazin-6-yl} 2-phenyl-3H-quinazolin-4-one Derivatives for their Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry An Adaptive Fuzzy Neural Network Technique for Coronavirus-based Bio-nano Communication Systems
Current Nanoscience